Michael Borne, MD
Retina Specialist · Jackson, MSNPI 1588750178
Payments from drug & device makers
Across 407 payments — averaging $2317.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ocular Therapeutix, Inc.$408K
- Boehringer Ingelheim$268K
- Apellis Pharmaceuticals, Inc.$106K
- Roche TCRC, Inc.$55K
- Regeneron Healthcare Solutions, Inc.$41K
- Regeneron$28K
- plus $37K from 15 others
Across 1 payment — averaging $10,650 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$11K
What the payments were for
- Consulting fees$13,1709%
- Speaking & faculty fees$111,62374%
- Travel & lodging$11,2847%
- Food & beverage$6,0244%
- Gifts$190%
- Entertainment$680%
- Ownership interest$3,4102%
- Other$5,5434%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ocular Therapeutix, Inc. | 75 | $407,520 |
| Boehringer Ingelheim | 37 | $268,256 |
| Apellis Pharmaceuticals, Inc. | 64 | $106,025 |
| Roche TCRC, Inc. | 11 | $55,409 |
| Regeneron Healthcare Solutions, Inc. | 71 | $41,409 |
| Regeneron | 20 | $27,667 |
| Astellas Pharma Global Development | 16 | $20,725 |
| US Retina LLC | 10 | $8,953 |
| Boehringer Ingelheim International GmbH | 45 | $5,022 |
| AbbVie(2 entities) | 22 | $599 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $566 |
| Genentech USA, Inc. | 6 | $235 |
| Bausch & Lomb Americas Inc. | 2 | $232 |
| Astellas Pharma US Inc | 6 | $146 |
| Biogen | 6 | $121 |
| Optos, Inc. | 1 | $68 |
| Alimera Sciences, Inc. | 3 | $58 |
| Coherus Oncology, Inc. | 3 | $50 |
| Dutch Ophthalmic, USA | 1 | $39 |
| Carl Zeiss Meditec, Inc. | 1 | $38 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few retina specialist providers in Mississippito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CombiganBrimonidine Tartrate/Timolol | 21 | $9,358 |
| LumiganBimatoprost | 16 | $7,607 |
| Prednisolone Acetate | 178 | $5,661 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 23 | $4,889 |
| Alphagan PBrimonidine Tartrate | 18 | $4,216 |
| Ketorolac Tromethamine | 70 | $3,204 |
| Travoprost | 14 | $2,120 |
| Latanoprost | 190 | $1,963 |
| Ofloxacin | 106 | $1,280 |
| Brimonidine Tartrate | 60 | $1,113 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 47 | $585 |
| Timolol Maleate | 63 | $541 |
| Dorzolamide Hcl | 30 | $529 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 38 | $418 |
| Flurbiprofen Sodium | 13 | $410 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan, Lumigan, Alphagan P | $599 | $21,18055 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few retina specialist providers in Mississippion file to place this against a meaningful peer group, so we don't.
Other retina specialist in Jackson
- Albert LinJackson$176K
- James BrownJackson$27K
- Joel HerringJackson$12K
- Khushboo AgrawalJackson$924
- Jorge CalzadaSouthaven$2M
- Martin ThomleyHattiesburg$2K
- Sean AllisonHattiesburg$2K
- Brian TieuRidgeland$1K
- Anne BarananoBiloxi$1K
- Cornelius ReganHattiesburg$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.